Patent intelligence · US
US 11890281
SHP2 phosphatase inhibitors and methods of making and using the same
SHP2 phosphatase inhibitors and methods of making and using the same
Patent details — US 11890281
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 6, 2024
- Expiration
- Feb 1, 2044
- Applicant
- Relay Therapeutics, Inc.
- Claims
- 27
- CPC classes
- A61K, A61K31/4985, A61K45/06
Quick answer
US 11890281 (SHP2 phosphatase inhibitors and methods of making and using the same) is held by Relay Therapeutics, Inc.. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Relay Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/4985, A61K45/06
More from Relay Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12331056
SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 12219327
Substituted isoindolines as PI3K-alpha inhibitors
granted -
US 12152034
FGFR inhibitors and methods of making and using the same
granted -
US 12138263
Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 12084447
SHP2 phosphatase inhibitors and methods of use thereof
granted -
US 11780845
FGFR inhibitors and methods of use thereof
granted -
US 11701354
Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
granted
Frequently asked questions
What is US patent 11890281?
US 11890281 (SHP2 phosphatase inhibitors and methods of making and using the same) is held by Relay Therapeutics, Inc.. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11890281?
Relay Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 11890281 expire?
Our index shows an expiration date of Feb 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.